Keywords: Abiraterone; Androgen receptor splice variant; Biomarker; Castration resistant; Enzalutamide; Prostate cancer;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Androgen receptor variants; Androgen receptor variant 7; Castration-resistant prostate cancer; Abiraterone; Enzalutamide;
Keywords: Castration-resistant prostate cancer; Treatment switch; Response; Progression; Circulating tumour cells; Abiraterone;
Keywords: Metastatic prostate cancer; Locally advanced prostate cancer; Hormone-naïve; Docetaxel; Abiraterone; Androgen deprivation therapy;
Keywords: Castration-resistant prostate cancer; Abiraterone; Enzalutamide; Metabolic syndrome; Inflammation;
Keywords: abiraterone; bone-targeted agents; castration-resistant prostate cancer; denosumab; electronic health records; enzalutamide; zoledronic acid;
Keywords: Abiraterone; Cardiac toxicity; CRPC; Enzalutamide; HSPC;
Keywords: Abiraterone; Chemo-naive; Chemotherapy; Docetaxel; Fatigue;
Keywords: Abiraterone; Circulating cell-free DNA; CRPC; Enzalutamide; Resistance;
Keywords: Castration-resistant prostate cancer; Prostate cancer; Androgen receptor; Androgen synthesis inhibitor; Androgen deprivation therapy; Novel androgen receptor antagonist; Abiraterone; Enzalutamide;
Keywords: Abiraterone; Androgen receptor degradation; Chemotherapy; CYP17 inhibition; Enzalutamide; Resistance;
Keywords: BRCA2; Circulating tumor DNA; Cell-free DNA; Liquid biopsy; Enzalutamide; Abiraterone; Castration-resistant prostate cancer; DNA repair;
Keywords: CYP450; Metabolic clearance; Drug-drug interactions; Abiraterone; Enzalutamide; Prostate cancer;
Keywords: abiraterone acetate; abiraterone; intestinal absorption; human intestinal fluids; clinical trial; food effect; supersaturation;
Keywords: Castration-resistant prostate cancer; Treatment outcome; Response; Circulating tumor cells; Abiraterone; Chemotherapy;
Keywords: Abiraterone; Androgen-receptor; Biomarkers; Cabazitaxel; Cell free DNA; Circulating tumor cells; Docetaxel; Enzalutamide; Metastatic castration-resistant prostate cancer; Taxanes;
Keywords: Prostate cancer; Castration resistant prostate cancer; Enzalutamide; Abiraterone; Docetaxel; Drug resistance;
Keywords: Prostate cancer; Castration-resistant; Treatment sequence; Abiraterone; Docetaxel; Enzalutamide; Cabazitaxel; Radium; Biomarkers;
Keywords: Abiraterone; Cabazitaxel; Castration-resistant prostate cancer; Estramustine; Thromboembolism
Keywords: Enzalutamide; Abiraterone acetate; Abiraterone; Docetaxel; Castration-resistant prostate cancer
Keywords: Abiraterone; Cabazitaxel; Enzalutamide; Metastatic castration-resistant prostate cancer; Taxanes
Keywords: Abiraterone; Antiandrogens; Drug resistance; Enzalutamide; Prostatic neoplasms; Castration resistant
Keywords: Abiraterone; Cabazitaxel; Castration-resistant prostate cancer; Docetaxel; Enzalutamide; Therapy sequence;
Keywords: Prostate cancer; Metastatic; Castration-resistant; Cabazitaxel; Abiraterone; Enzalutamide;
Keywords: CRPC; Novel treatments; Abiraterone; Enzalutamide; Cabazitaxel; Sipuleucel T; Radium-223;
Keywords: Metastatic castration-resistant prostate cancer; Consensus; Radium 223 dichloride; Abiraterone; Enzalutamide; Docetaxel; Circulating tumour cells; Sipuleucel-T; Cabazitaxel; Denosumab;
Keywords: Castration-resistant prostate cancer; Enzalutamide; Abiraterone; Radium-223; Cabazitaxel; Docetaxel; Bone metastases;
Keywords: Prostate cancer; Castration-resistance; Sipuleucel-T; Cabazitaxel; Abiraterone; Enzalutamide; Denosumab
Keywords: Castration resistant prostate cancer; CRPC; Elderly; Abiraterone; Cabazitaxel; Sipuleucel-T; Enzalutamide; Alpharadin; Denosumab;
Keywords: Abiraterone; Prostate; Health; Quality of life; Outcome assessment;
Keywords: prostatic neoplasms; polymorphism, single nucleotide; abiraterone; treatment failure; biomarkersAA, abiraterone acetate; AR, androgen receptor; FDR, false discovery rate; HSD, 17β-hydroxysteroid dehydrogenase; IGF, insulin-like growth factor; LN, lymph no
Keywords: Metastatic prostate cancer; Castration-resistant; Chemotherapy; Abiraterone; Elderly; Frailty; Activities of daily living; Physical performance; Falls; Quality of life
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer
Keywords: Abiraterone; HSD3B1; Metastatic prostate cancer; Predictive biomarker;
Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide
Keywords: Prostate cancer; Circulating tumor cell; Androgen receptor; Synaptophysin; Abiraterone; Enzalutamide;
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study
Keywords: Abiraterone; Testosterone; Prostate-specific antigen; CYP17 inhibitor; Metastatic castrate-resistant prostate cancer;
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
Keywords: DNA repair; Germline; Mutation; Abiraterone; Enzalutamide;
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry
Keywords: Abiraterone; Cabazitaxel; Fatigue; Pain; Quality of life;
Quantitation of the anticancer drug abiraterone and its metabolite Î(4)-abiraterone in human plasma using high-resolution mass spectrometry
Keywords: High-resolution mass spectrometry; Abiraterone; Prostate cancer; Pharmacokinetics; Metabolomics;
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives
Keywords: De novo metastatic castration sensitive prostate cancer; mCSPC; Prostate cancer; Prognostic; Docetaxel; Abiraterone;
A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients
Keywords: 3β-HSD1; 3β-hydroxysteroid dehydrogenase/Î5â4 isomerase 1; CYP17A1; 17αâhydroxylase/17,20âlyase; Î4A; Î4-abiraterone; ABI; abiraterone; ADT; androgen-deprivation therapy; Cmin; mean of trough plasma concentrations measured during the first thr
Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
Keywords: Abiraterone; Chemohterapy-naive; Enzalutamide; mCRPC; Sequential treatment;
Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors - abiraterone and galeterone - with human sterol 14α-demethylase (CYP51A1)
Keywords: CYP51A1; Abiraterone; Galeterone; Absorbance spectra; Electrochemistry; Molecular modeling;
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials
Keywords: mCRPC; tSRE; rPFS; Abiraterone; Enzalutamide;
Adult UrologyOncology: Prostate/Testis/Penis/UrethraAR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
Keywords: prostatic neoplasms; castration-resistant; neoplasm metastasis; receptors; androgen; biomarkers; tumor; abiraterone; ALP; alkaline phosphatase; AR; androgen receptor; CRPC; castration resistant prostate cancer; Ct; cycle threshold; CTC; circulating tumor
Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column
Keywords: Prostate cancer; Abiraterone; LC-MS/MS; Method validation; Metabolites;
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program
Keywords: Abiraterone; Androgen receptor antagonist; Antihormonal drugs; PSA; Treatment sequence;
QTAIM and NCI analysis of intermolecular interactions in steroid ligands binding a cytochrome P450 enzyme - Beyond the most obvious interactions
Keywords: Cytochrome P450; CYP17; Abiraterone; QTAIM; NCI; Exotic HH bond;
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia
Keywords: Abiraterone; Chemotherapy-naïve; Metastatic castration-resistant prostate cancer; Prostate specific antigen; Prednisone;
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: AÂ systematic review and meta-analysis
Keywords: Prostate cancer; Metastases; Abiraterone; Systematic review; Meta-analysis; Androgen deprivation therapy;
Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS
Keywords: Bicalutamide; Enzalutamide; Abiraterone; Tandem mass spectrometry; Metabolites; Assay; Validation;